Purchase this article with an account.
C.–P. Lin, C.–H. Yang, F.–A. Lin, W.–L. Chen; Treatment of Sjogren's Syndrome With Anti–P–selectin Glycoprotein Ligand–1 Monoclonal Antibody in NOD Mice . Invest. Ophthalmol. Vis. Sci. 2005;46(13):986.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: P–selectin glycoprotein ligand–1 has been shown to be involved in T lymphocyte traficking. Its monoclonal antibody has been shown to induce apoptosis in activated T–cells. To study the effect of anti–CD162 (p–selectin glycoprotein ligand–1) monocloanl antibody on the course of Sjogren's syndrome in NOD mice. Methods: Anti–CD162 monoclonal antibody was raised in hamster and was injected intraperitoneally in treatment goups of NOD mice at the age of 8, 9 and 10 weeks. Total hamster IgG was used in control group. Tear secretion, both basal and stimulated with pilocarpine, and urine sugar were measured at different time points until the age of 30 weeks. Histopathology of lacrimal gland, salivary gland and pancrease was also studied. Results: Tear secretion was preserved in treatment group at 22, 25 and 30 weeks of age. Histopathology showed significant less lymphocytic infiltraion in lacrimal gland, salivary gland and pancreatic islet. In treatment group, 80% and 70% of mice remained diabetes free at the age of 22 and 30 weeks respectively. Only 20% of control group remained diabetes free. Conclusions: Anti–CD162 monocloanl antibody could prevent Sjogren syndrome as well as diabetes in NOD mouse, possibly by suppressing lymphocytic infiltraion.
This PDF is available to Subscribers Only